DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

JP Morgan Upgrades Mirati Therapeutics to Neutral, Announces $88 Price Target

JP Morgan analyst Anupam Rama upgrades Mirati Therapeutics (NASDAQ:MRTX) from Underweight to Neutral and announces $88 price target.

Benzinga · 03/12/2020 09:45

JP Morgan analyst Anupam Rama upgrades Mirati Therapeutics (NASDAQ:MRTX) from Underweight to Neutral and announces $88 price target.